Mankind Pharma Ltd 06 Nov 2024 12:00 AM
Mankind Pharma receives reaffirmation in credit rating from CRISIL,
Mankind Pharma has received reaffirmation in credit ratings from CRISIL as under:Commercial paper (Rs 5,000 crore) - CRISIL A1+Non convertible debentures (Rs 4,600 crore) - CRISIL AA+/ Stable Non convertible debentures (Rs 400 crore) - CRISIL AA+/ Stable Total bank loan facilities rated (Rs 1,250 crore) - CRISIL AA+/ Stable Powered by Capital Market - Live News
Mankind Pharma Ltd 05 Nov 2024 12:00 AM
Mankind Pharma consolidated net profit rises 30.43% in the September 2024 quarter,
Net profit of Mankind Pharma rose 30.43% to Rs 653.47 crore in the quarter ended September 2024 as against Rs 501.03 crore during the previous quarter ended September 2023. Sales rose 13.60% to Rs 3076.51 crore in the quarter ended September 2024 as against Rs 2708.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3076.512708.10 14 OPM %27.6325.21 - PBDT954.94737.48 29 PBT849.32640.99 33 NP653.47501.03 30 Powered by Capital Market - Live News
Mankind Pharma Ltd 25 Oct 2024 12:00 AM
Mankind Pharma to convene board meeting,
Mankind Pharma will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live News
Mankind Pharma Ltd 30 Sep 2024 12:00 AM
Mankind Pharma receives ratings action from ICRA,
Mankind Pharma has received reaffirmation in credit rating for non-convertible debentures (Rs 4,600 crore) at ICRA AA+; Stable. The company has been assigned the rating ICRA A1+ and ICRA AA+; Stable for commercial papers (Rs 5,000 crore), non-convertible debentures (Rs 400 crore) and bank facilities (Rs 1,250 crore). Powered by Capital Market - Live News
Mankind Pharma Ltd 18 Sep 2024 12:00 AM
Mankind Pharma to conduct board meeting,
Mankind Pharma will hold a meeting of the Board of Directors of the Company on 20 September 2024.Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now